drugset / Trial / NCT03929510
Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600.
Non-randomizedSequentialOpen-labelBasic science
Summary
This study will investigate the absorption, distribution, metabolism and excretion (ADME) of 14C PF-06651600 and characterize plasma, fecal and urinary radioactivity and identify any metabolites, if possible, of 14C PF-06651600 in humans.
Timeline
- Start
- 2019-04-23
- Primary completion
- 2019-07-05
- Completion
- 2019-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ritlecitinib | Small molecule | 60 ug | Oral |
| Subject | Ritlecitinib | Small molecule | 200 mg | Oral |
Indications
No indication recorded.